Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4

CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 bindi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naroa Serna, José Vicente Carratalá, Oscar Conchillo-Solé, Carlos Martínez-Torró, Ugutz Unzueta, Ramón Mangues, Neus Ferrer-Miralles, Xavier Daura, Esther Vázquez, Antonio Villaverde
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	antimicrobial peptides nanoparticles fusion proteins inhibition of biofilm formation multivalent drugs Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/6ce775b1fd7147279d540e20658bd677
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ce775b1fd7147279d540e20658bd677
record_format	dspace
spelling	oai:doaj.org-article:6ce775b1fd7147279d540e20658bd6772021-11-25T18:41:52ZAntibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR410.3390/pharmaceutics131119221999-4923https://doaj.org/article/6ce775b1fd7147279d540e20658bd6772021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1922https://doaj.org/toc/1999-4923CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over <i>Escherichia coli</i>, <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms.Naroa SernaJosé Vicente CarrataláOscar Conchillo-SoléCarlos Martínez-TorróUgutz UnzuetaRamón ManguesNeus Ferrer-MirallesXavier DauraEsther VázquezAntonio VillaverdeMDPI AGarticleantimicrobial peptidesnanoparticlesfusion proteinsinhibition of biofilm formationmultivalent drugsPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1922, p 1922 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antimicrobial peptides nanoparticles fusion proteins inhibition of biofilm formation multivalent drugs Pharmacy and materia medica RS1-441
spellingShingle	antimicrobial peptides nanoparticles fusion proteins inhibition of biofilm formation multivalent drugs Pharmacy and materia medica RS1-441 Naroa Serna José Vicente Carratalá Oscar Conchillo-Solé Carlos Martínez-Torró Ugutz Unzueta Ramón Mangues Neus Ferrer-Miralles Xavier Daura Esther Vázquez Antonio Villaverde Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
description	CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over <i>Escherichia coli</i>, <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms.
format	article
author	Naroa Serna José Vicente Carratalá Oscar Conchillo-Solé Carlos Martínez-Torró Ugutz Unzueta Ramón Mangues Neus Ferrer-Miralles Xavier Daura Esther Vázquez Antonio Villaverde
author_facet	Naroa Serna José Vicente Carratalá Oscar Conchillo-Solé Carlos Martínez-Torró Ugutz Unzueta Ramón Mangues Neus Ferrer-Miralles Xavier Daura Esther Vázquez Antonio Villaverde
author_sort	Naroa Serna
title	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
title_short	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
title_full	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
title_fullStr	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
title_full_unstemmed	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
title_sort	antibacterial activity of t22, a specific peptidic ligand of the tumoral marker cxcr4
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6ce775b1fd7147279d540e20658bd677
work_keys_str_mv	AT naroaserna antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT josevicentecarratala antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT oscarconchillosole antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT carlosmartineztorro antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT ugutzunzueta antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT ramonmangues antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT neusferrermiralles antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT xavierdaura antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT esthervazquez antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4 AT antoniovillaverde antibacterialactivityoft22aspecificpeptidicligandofthetumoralmarkercxcr4
_version_	1718410777134628864

Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4

Ejemplares similares